The invention relates to oligofluorinated coatings and their use in drag delivery. The oligofluorinated coatings are compositions comprising formula (XVII). These coatings are used in a method of delivering a biologically active agent to a tissue surface in a mammalian tissue. This method occurs by contacting the surface with the coating including an oligofluorinated oligomer and a biologically active agent wherein the coating resides on the tissue surface and release the biologically active agent to the tissue surface.
A61L 29/16 - Biologically active materials, e.g. therapeutic substances
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The invention relates to extracorporeal blood circuits, and components thereof (e.g., hollow fiber membranes, potted bundles, and blood tubing), including 0.005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.
B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
A61L 29/16 - Biologically active materials, e.g. therapeutic substances
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
The invention relates to carbonate-linked surface modifying macromolecules and admixtures thereof. The macromolecules comprise surface active polyfluoroorgano groups, polyalkylene oxide groups and a soft segment. The groups and segments are joined through carbonate linkages. The admixtures can be used in industrial and medical applications where enhanced surface properties are desirable (e.g. surface properties reducing or preventing biofouling, immobilization of biomolecules, or denaturation of certain biomolecules).
The disclosure features ocular inserts for the sustained release of steroids in the treatment ocular conditions. Said ocular inserts are articles formed from a compound of formula D1-L-D2 (A-I), wherein D1 and D2 are steroid radicals selected from the group consisting of an antibiotic steroid, a glucocorticoid steroid, an anti-angiogenic steroid, an intraocular pressure lowering steroid, and a corticosteroid; and L is a linker covalently linking D1 to D2. The article is a fiber, fiber mesh, woven fabric, non- woven fabric, pellet, cylinder, microparticle, nanoparticle, or shaped article. Also disclosed are carbonate and carbonate ester linked dimers of corticosteroids linked at the 3-hydroxyl, the 11-hydroxyl, the 17-hydroxyl, or the 21-hydroxyl positions of the steroid.
C07J 5/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, and substituted in position 21 by only one singly bound oxygen atom
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 9/00 - Medicinal preparations characterised by special physical form
C07J 75/00 - Processes for the preparation of steroids, in general
8.
DIMERIC DEXAMETHASONE PRODRUG COMPOSITIONS AND USES THEREOF
Dimeric dexamethasone prodrugs (I) and articles formed from said dimeric dexamethasone prodrugs are disclosed. The articles comprising Dimeric dexamethasone prodrugs can be heat molded, injection molded, blow molded, electrospun, electrosprayed, or extruded to form a fiber, fiber mesh, woven fabric, non-woven fabric, pellet, cylinder, micro particle, nanoparticle, or shaped article, including implants, from which the dexamethasone prodrug dimer is released in a controlled fashion.
C07J 5/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, and substituted in position 21 by only one singly bound oxygen atom
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 9/00 - Medicinal preparations characterised by special physical form
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
D01F 6/00 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof
9.
GLASS FORMULATIONS COMPRISING STEROID DIMERS AND USES THEREOF
Steroid dimers and articles formed from steroid dimers are disclosed. Said steroid dimers are represented by D1-L-D2 wherein D1 and D2 are steroid moieties and L is a covalent linker. The articles comprising the steroid dimers can be machined, molded, emulsion-processed, electrospun, electrosprayed, blow molded, fiber spun, wet spun, dry spun, melt spun, heat spun, gel spun, or extruded to form a fiber, fiber mesh, woven fabric, non-woven fabric, pellet, cylinder, microparticle, nanoparticle, or shaped article. Said articles are used as drug delivery devices (e.g. an implant) for the extended delivery of a steroid to a subject.
C07J 5/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, and substituted in position 21 by only one singly bound oxygen atom
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 9/00 - Medicinal preparations characterised by special physical form
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
C07J 75/00 - Processes for the preparation of steroids, in general
D01F 6/00 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof
Disclosed are implantable heart valves having a surface modified to reduce the risk of thrombi formation post implantation into a subject. The prosthetic valve can include one or more leaflets comprising a base polymer admixed with an oligofluorinated additive.
Disclosed are vascular grafts having a surface modified to reduce the risk of thrombi formation post implantation into a subject. The vascular graft can include a tubular structure comprising a base polymer admixed with an oligofluorinated additive.
The present invention relates to polyvinvyl chloride (PVC) admixtures with plasticizers and surface modifying macromolecules. In accordance with embodiments, articles formed from the compositions disclosed herein may reduce leaching of plasticizers.
Disclosed are implantable glucose sensors having a biostable surface. The implantable glucose sensor includes a glucose detector and an enclosure defining a boundary between an internal space and an external space. The enclosure includes a semipermeable biointerface film containing a base polymer and a biostabilizing additive. The semipermeable biointerface film has a biostable surface and is permeable to glucose. The working electrode is disposed inside the internal space, and the biostable surface faces the external space or faces both the internal and the external spaces. Also disclosed are methods of preparation of the semipermeable biointerface films adapted for use in the implantable glucose sensors. Further, disclosed are methods of monitoring glucose levels in a subject through the use of an implantable glucose sensor. The implantable glucose sensor may be an implantable electrochemical glucose sensor, in which the glucose detector is a working electrode. Alternatively, the implantable glucose sensor may be an implantable optical glucose sensor, in which the glucose detector is a glucose recognition element including a glucose-binding fluorophore.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
The invention relates to extracorporeal blood circuits, and components thereof (e.g., hollow fiber membranes, potted bundles, and blood tubing), including 0.005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.
F16L 11/04 - Hoses, i.e. flexible pipes made of rubber or flexible plastics
B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
B29C 47/00 - Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor (extrusion blow-moulding B29C 49/04)
The invention relates to ester-linked surface-modifying macromolecules and admixtures thereof as shown below by the representative compounds. The admixtures can be used in industrial and medical applications where enhanced surface properties are desirable (e.g., surface properties reducing or preventing biofouling, immobilization of biomolecules, or denaturation of certain biomolecules).
The invention features a packaging material including a film having a barrier layer formed from an admixture containing a base polymer and a surface-modifying macromolecule. The invention also features containers made from the packaging materials and methods of storing a good.
The invention relates to oligofluorinated coatings and their use in drag delivery. The oligofluorinated coatings are compositions comprising formula (XVII). These coatings are used in a method of delivering a biologically active agent to a tissue surface in a mammalian tissue. This method occurs by contacting the surface with the coating including an oligofluorinated oligomer and a biologically active agent wherein the coating resides on the tissue surface and release the biologically active agent to the tissue surface.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
18.
Antithrombogenic hollow fiber membranes and filters
The invention relates to extracorporeal blood circuits, and components thereof (e.g., hollow fiber membranes, potted bundles, and blood tubing), including 0.005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.
B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
B29C 47/00 - Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor (extrusion blow-moulding B29C 49/04)
The invention relates to compounds that include biologically active agents (e.g., compounds according to any of formulas (I) and (I-A) that can be used for effective drug release, e.g., as coatings for medical devices. Use of these compounds in the coating of surfaces can allow for long-term drug release as well as imparting uniform coatings with little phase separation compared to, e.g., the parent biologically active agent.
A61L 31/16 - Biologically active materials, e.g. therapeutic substances
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61L 15/22 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
The invention relates to oligofluorinated coatings and their use in drag delivery The oligofluorinated coatings are compositions comprising formula (XVII). These coatings are used in a method of delivering a biologically active agent to a tissue surface in a mammalian tissue This method occurs by contacting the surface with the coating including an oligofluorinated oligomer and a biologically active agent wherein the coating resides on the tissue surface and release the biologically active agent to the tissue surface.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
The invention relates to oligofluorinated coatings and their use in drag delivery The oligofluorinated coatings are compositions comprising formula (XVII). These coatings are used in a method of delivering a biologically active agent to a tissue surface in a mammalian tissue This method occurs by contacting the surface with the coating including an oligofluorinated oligomer and a biologically active agent wherein the coating resides on the tissue surface and release the biologically active agent to the tissue surface.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
C07D 303/08 - Compounds containing oxirane rings with hydrocarbon radicals, substituted by halogen atoms, nitro radicals or nitroso radicals
C07D 203/06 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 403/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 263/08 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
C07K 2/00 - Peptides of undefined number of amino acidsDerivatives thereof
C07H 99/00 - Subject matter not provided for in other groups of this subclass
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61P 25/00 - Drugs for disorders of the nervous system
B05D 3/02 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by baking
23.
Antithrombogenic hollow fiber membranes and filters
The invention relates to extracorporeal blood circuits, and components thereof (e.g., hollow fiber membranes, potted bundles, and blood tubing), including 0.005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.
A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
B29C 47/00 - Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor (extrusion blow-moulding B29C 49/04)
The invention relates to extacorporeal blood circuits, and components thereof (e.g., hollow fiber membranes, potted bundles, and blood tubing), including 0.005% to 10% (w/w) surface modifying macromolecule. The extracorporeal blood circuits have an antithrombogenic surface and can be used in hemofiltration, hemodialysis, hemodiafiltration, hemoconcentration, blood oxygenation, and related uses.
The invention features grafted polymer systems for use in medical devices and/or for the delivery of active agents. The grafted polymers include at least one transport moiety, a linear backbone segment, and a pendant segment.
The invention relates to surface modifying macromolecules (SMMs) having high degradation temperatures and their use in the manufacture of articles made from base polymers which require high temperature processing. The surface modifier is admixed with the base polymer to impart alcohol and water repellency properties.
The invention relates to graftable polymers comprising biologically active agents and the use of such polymers in the manufacture of shaped articles, such as implantable medical devices and catheters. The graftable polymers are covalently grafted to a surface via one or more grafting moieties incorporated into the pharmaceutically-active graftable polymer. The coated articles of the invention can further comprise tie-coats, and the ratio of polymeπtie coat can be used to adjust the rate of drug elution.
Compositions comprising the combination of a membrane active biocide and a second agent selected from fluoroquinolones, ammoglycodies, β-lactams, glycopeptide antibiotics, sufonamides and antifungal azoles and their use in the treatment or prevention of bacterial or fungal infections Preferred membrane active biocides are selected from chlorohexidme, polymyxin B-nonapeptide, bacitracin, aztreonam, benzlakomum salts and metal chelators The active ingredients can be in either monomer or polymeric form.
A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61L 15/46 - Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
A61L 15/64 - Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
A61L 2/16 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor using chemical substances
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
A61L 27/58 - Materials at least partially resorbable by the body
A61L 29/16 - Biologically active materials, e.g. therapeutic substances
A61L 31/14 - Materials characterised by their function or physical properties
A61L 31/16 - Biologically active materials, e.g. therapeutic substances
The invention features the use of a matrix consisting of low molecular weight components for use as a self-eliminating coating for implantable medical devices. The matrix coatings can be used to enhance biocompatibility and to control the local delivery of biologically active agents.
The invention features the use of a matrix consisting of low molecular weight components for use as a self-eliminating coating for implantable medical devices. The matrix coatings can be used to enhance biocompatibility and to control the local delivery of biologically active agents.
The invention relates to surface modifying macromolecules (SMMs) having high degradation temperatures and their use in the manufacture of articles made from base polymers which require high temperature processing. The surface modifier is admixed with the base polymer to impart alcohol and water repellency properties.
The invention features biodegradable polymers for the delivery of biologically active agents. The polymers include at least one biologically active agent covalently attached via a polyamide linker susceptible to selective hydrolysis by peptidase enzymes. Hydrolysis of the polyamide linker releases the biologically active agent in vivo.
C08G 69/00 - Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 9/00 - Medicinal preparations characterised by special physical form
The invention features grafted polymer systems for use in medical devices and/or for the delivery of active agents. The grafted polymers include at least one transport moiety, a linear backbone segment, and a pendant segment.
A61L 31/16 - Biologically active materials, e.g. therapeutic substances
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 9/00 - Drugs for disorders of the cardiovascular system
C08L 51/08 - Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bondsCompositions of derivatives of such polymers grafted on to macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
The invention features alcohol and water repellent non-woven fabrics made from synthetic polymer fibers. The fibers comprise a surface modifier admixed with the synthetic polymer to impart alcohol and water repellency properties.
B32B 25/04 - Layered products essentially comprising natural or synthetic rubber comprising rubber as the main or only constituent of a layer, next to another layer of a specific substance
The invention features polymers noncovalently complexed with a biologically active agent. The polymer complexes include at least one shielding moiety covalently tethered to at least one complexing moiety, which is complexed with at least one biologically active agent.
A01N 25/00 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Biomaterials, namely, surface modifying macro-molecules for incorporation into surfaces of medical devices to enhance compatibility between medical devices and body tissues and fluids for use in the manufacture of artificial implants and medical devices; chemicals, namely, biodegradable drug polymers formulated with pharmaceuticals for use in the manufacture of artificial implants and medical devices; surface modifying macro-molecules designed to deliver bio-active reagents to surfaces for use in the manufacture of artificial implants and medical devices
01 - Chemical and biological materials for industrial, scientific and agricultural use
35 - Advertising and business services
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Biomaterials namely, surface modifying macro-molecules for incorporation into surfaces of medical devices to enhance compatability between medical devices and body tissues and fluids; chemicals namely, biodegradable drug polymers formulated with pharmaceuticals; surface modifying macro-molecules designed to deliver bio-active reagents to surfaces. (1) Operation of a business engaged in the sale of biomaterials, surface modifying molecules and polymers for use in the medical field to enhance compatibility between medical devices and implants and body tissues and fluids.
(2) Operation of a business engaged in the development and production of biomaterials, surface modifying molecules and polymers for use in the medical field to enhance compatability between medical devices and implants and body tissues and fluids; Laboratory research and development in the field of biomedical polymer technologies, drug delivery systems and medical devices; operation of a web site providing information in the field of biomedical polymer technologies and drug delivery systems.
